title: Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients.
abstract: OBJECTIVE
  To evaluate mantle radiotherapy (MRT) alone as the initial therapy of patients with clinical stage (CS) I-II Hodgkin's disease (HD).
  
  
  METHODS
  We performed a retrospective study of patients treated with MRT alone for CS I-II supradiaphragmatic HD between 1969 and 1994. Prognostic factor analysis was performed for progression-free survival (PFS) and overall survival (OS). Outcome was also assessed in favorable cohorts defined in the literature.
  
  
  RESULTS
  There were 261 eligible patients. The median follow-up period for surviving patients was 8.4 years (range, 1.8 to 27.4 years). The 10-year OS rate was 73%. Multifactor analysis for OS showed that age was the only important prognostic factor. The 10-year PFS rate was 58%. On multifactor analysis for PFS, the most important prognostic factors were clinical stage, B symptoms, histology, number of sites, and tumor bulk. The 10-year PFS rate for lymphocyte-predominant disease was 81% for stage I and 78% for stage II. In favorable patient cohorts defined in the literature, the 10-year PFS rate ranged from 70% to 73% for the whole group and from 71% to 90% in patients with favorable stage I disease, but only from 48% to 57% in patients with favorable stage II disease. On competing-risks analysis, the cumulative 10-year incidence of first site of failure in the para-aortic/splenic region alone was 10.5%. Sixty percent of relapsed patients remain progression-free at 10 years after chemotherapy salvage.
  
  
  CONCLUSIONS
  These results support the use of MRT alone in patients with favorable CS I HD and CS I-II HD with lymphocyte-predominant histology. The remainder of patients with CS I-II HD require more intensive treatment.
authors.affiliation: Division of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia. awirth@petermac.unimelb.edu.au
authors.forename: A
authors.initials: A
authors.lastname: Wirth
authors.forename: M
authors.initials: M
authors.lastname: Chao
authors.forename: J
authors.initials: J
authors.lastname: Corry
authors.forename: C
authors.initials: C
authors.lastname: Laidlaw
authors.forename: K
authors.initials: K
authors.lastname: Yuen
authors.forename: G
authors.initials: G
authors.lastname: Ryan
authors.forename: D
authors.initials: D
authors.lastname: Byram
authors.forename: S
authors.initials: S
authors.lastname: Davis
authors.forename: J
authors.initials: J
authors.lastname: Kiffer
authors.forename: G
authors.initials: G
authors.lastname: Quong
authors.forename: K
authors.initials: K
authors.lastname: Liew
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate